📊 ERNAW Key Takeaways
Is Ernexa Therapeutics Inc. (ERNAW) a Good Investment?
Ernexa Therapeutics is a pre-revenue pharmaceutical company with severe operational losses and negative cash flows. Despite a spike in revenue (+756% YoY), absolute sales remain negligible at $582K while operating losses reached $9.3M, indicating the company is burning cash with minimal commercial traction. With only $1.9M in cash and negative free cash flow of $7.1M annually, the company faces critical liquidity constraints within months unless it secures additional financing.
Ernexa Therapeutics shows severe fundamental weakness despite sharp revenue growth, as its scale remains far too small to offset deeply negative operating economics. The company is burning cash rapidly, has only modest cash relative to annual operating cash outflows, and its near-1.0x liquidity profile leaves little margin for error. Growth quality appears weak because improving revenue has not translated into meaningful progress toward profitability or balance sheet resilience.
Why Buy Ernexa Therapeutics Inc. Stock? ERNAW Key Strengths
- Strong gross margin of 83.5% suggests product pricing power and efficient manufacturing when revenue scales
- Low debt-to-equity ratio of 0.22x indicates minimal leverage and financial flexibility for equity financing
- Revenue growth of 756% YoY demonstrates emerging commercial activity from previous near-zero baseline
- Revenue grew 755.9% year over year, indicating some top-line momentum
- Gross margin of 83.5% suggests favorable unit economics before operating expenses
- Debt levels are relatively low versus equity, with debt-to-equity of 0.22x
ERNAW Stock Risks: Ernexa Therapeutics Inc. Investment Risks
- Severe cash burn of $7.1M in free cash flow with only $1.9M cash on hand creates imminent liquidity crisis
- Massive operating losses and negative margins across all profitability metrics indicate unsustainable business model
- Negligible revenue base of $582K demonstrates lack of commercial product-market fit or meaningful market adoption
- High risk of dilutive financing or equity collapse required to meet operational cash needs
- Operating and net losses remain extremely large relative to revenue, with operating margin of -1601.2% and net margin of -2419.9%
- Cash burn is severe, with negative operating cash flow of $7.02M and free cash flow of -$7.05M against only $1.88M of cash
- Liquidity is tight, with current and quick ratios of 1.01x, raising funding and going-concern risk if losses persist
Key Metrics to Watch
- Cash runway and date of next financing requirement
- Quarterly revenue growth trajectory and path to positive gross profit contribution
- Operating expense reduction and timeline to cash flow breakeven
- Clinical development milestones and regulatory approval progress for pipeline assets
- Cash runway relative to quarterly operating cash burn
- Trend in operating expenses versus revenue growth
Ernexa Therapeutics Inc. (ERNAW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Ernexa Therapeutics Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ERNAW Profit Margin, ROE & Profitability Analysis
ERNAW vs Healthcare Sector: How Ernexa Therapeutics Inc. Compares
How Ernexa Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ernexa Therapeutics Inc. Stock Overvalued? ERNAW Valuation Analysis 2026
Based on fundamental analysis, Ernexa Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ernexa Therapeutics Inc. Balance Sheet: ERNAW Debt, Cash & Liquidity
ERNAW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ernexa Therapeutics Inc.'s revenue has declined by 98% over the 5-year period, indicating business contraction. The most recent EPS of $-48.96 indicates the company is currently unprofitable.
ERNAW Revenue Growth, EPS Growth & YoY Performance
ERNAW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $487.0K | -$1.2M | $-0.15 |
| Q2 2025 | $47.0K | -$3.1M | $-0.61 |
| Q1 2025 | $47.0K | -$6.6M | $-0.15 |
| Q3 2024 | $51.0K | -$5.6M | $-1.03 |
| Q2 2024 | $47.0K | -$4.5M | $-0.85 |
| Q1 2024 | N/A | -$5.4M | $-1.06 |
| Q3 2023 | N/A | -$5.6M | $-1.03 |
| Q3 2020 | $1.5M | -$351.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ernexa Therapeutics Inc. Dividends, Buybacks & Capital Allocation
ERNAW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ernexa Therapeutics Inc. (CIK: 0000748592)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ERNAW
What is the AI rating for ERNAW?
Ernexa Therapeutics Inc. (ERNAW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ERNAW's key strengths?
Claude: Strong gross margin of 83.5% suggests product pricing power and efficient manufacturing when revenue scales. Low debt-to-equity ratio of 0.22x indicates minimal leverage and financial flexibility for equity financing. ChatGPT: Revenue grew 755.9% year over year, indicating some top-line momentum. Gross margin of 83.5% suggests favorable unit economics before operating expenses.
What are the risks of investing in ERNAW?
Claude: Severe cash burn of $7.1M in free cash flow with only $1.9M cash on hand creates imminent liquidity crisis. Massive operating losses and negative margins across all profitability metrics indicate unsustainable business model. ChatGPT: Operating and net losses remain extremely large relative to revenue, with operating margin of -1601.2% and net margin of -2419.9%. Cash burn is severe, with negative operating cash flow of $7.02M and free cash flow of -$7.05M against only $1.88M of cash.
What is ERNAW's revenue and growth?
Ernexa Therapeutics Inc. reported revenue of $582.0K.
Does ERNAW pay dividends?
Ernexa Therapeutics Inc. does not currently pay dividends.
Where can I find ERNAW SEC filings?
Official SEC filings for Ernexa Therapeutics Inc. (CIK: 0000748592) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ERNAW's EPS?
Ernexa Therapeutics Inc. has a diluted EPS of $-2.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ERNAW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ernexa Therapeutics Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ERNAW stock overvalued or undervalued?
Valuation metrics for ERNAW: ROE of -586.6% (sector avg: 15%), net margin of -2,419.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ERNAW stock in 2026?
Our dual AI analysis gives Ernexa Therapeutics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ERNAW's free cash flow?
Ernexa Therapeutics Inc.'s operating cash flow is $-7.0M, with capital expenditures of $37.0K. FCF margin is -1,212.0%.
How does ERNAW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,419.9% (avg: 12%), ROE -586.6% (avg: 15%), current ratio 1.01 (avg: 2).